Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

REVEAL: Randomized EValuation of the Effects of Anacetrapib Through Lipid-modification (REVEAL)

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborator:
Merck Sharp & Dohme Corp.
Information provided by (Responsible Party):
University of Oxford
ClinicalTrials.gov Identifier:
NCT01252953
First received: November 24, 2010
Last updated: October 25, 2016
Last verified: October 2016